HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924Paul Haluska, Charles Erlichman|Molecular Cancer Therapeutics|2008Cited by 101
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancerDouglas Yee, Jane Perlmutter, Paul Haluska et al.|npj Breast Cancer|2021Cited by 29